Abstracts tagged "PAD"

Abstract Number: 77 • 2018 ACR/ARHP Annual Meeting
Single Nucleotide Polymorphism in the Gene Encoding Peptidylarginine Deiminase 4 Correlates with Reduced Neutrophil Extracellular Traps and Anti-Histone Antibodies in Rheumatoid Arthritis
Aisha M. Mergaert¹, Mandar Bawadekar², Thai Q. Nguyen¹, Steven J. Schrodi^3,4 and Miriam A. Shelef^2,5, ¹University of Wisconsin - Madison, Madison, WI, ²Department of Medicine, Division of Rheumatology, University of Wisconsin - Madison, Madison, WI, ³Center for Precision Medicine Research, Marshfield Clinic Research Institute, Marshfield, WI, ⁴Computation and Informatics in Biology and Medicine, University of Wisconsin - Madison, Madison, WI, ⁵William S. Middleton Memorial Veterans Hospital, Madison, WI
Background/Purpose: In neutrophils, peptidylarginine deiminase 4 (PAD4) citrullinates histones allowing chromatin unraveling and neutrophil extracellular trap (NET) formation. NETs are increased and display proteins targeted…
Abstract Number: 1461 • 2018 ACR/ARHP Annual Meeting
Peptidylarginine Deiminase-4 Antibodies Are Not Associated with Worse RA Activity, Symptoms or Impacts
Dana DiRenzo¹, Erika Darrah², Susan J. Bartlett^3,4, Clifton O. Bingham III⁴ and Laura C. Cappelli¹, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Medicine/Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ⁴Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Antibodies to peptidylarginine deiminase (PAD) enzymes have been implicated in the pathogenesis of RA. Previous studies have shown that patients with PAD4 antibodies…
Abstract Number: 1471 • 2018 ACR/ARHP Annual Meeting
ECV304 Cells Self-Citrullinate Proteins Targeted By Anti-Citrullinated Protein/Peptide Autoantibodies from Rheumatoid Arthritis Patients
Natalia Regine de Franca Shimabukuro^1,2, Maximilien Lora¹, Mariana Useche³, Zhijie Zhou⁴, Joyce Rauch⁵, Luis Eduardo Coelho Andrade², Henri Menard¹ and Ines Colmegna⁶, ¹The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Federal University of São Paulo, São Paulo, Brazil, ³Medicine, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Aurora Medical Centre, Oshkosh, WI, ⁵Division of Rheumatology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁶The Research Institute of the McGill University Health Centre, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada
Background/Purpose: Anti-citrullinated protein/peptide autoantibodies (ACPAs) define a major subset of rheumatoid arthritis (RA) patients. Cyclic citrullinated peptides (CCP) are commonly used as the antigen for…
Abstract Number: 2056 • 2018 ACR/ARHP Annual Meeting
Citrullination Is Not a Determinant in the Lack of Tolerance to Peptidylarginine Deiminase 2 and 4 in Rheumatoid Arthritis
Pooja Naik¹, Ryan Davis², Jon T. Giles³, Felipe Andrade⁴ and Erika Darrah⁵, ¹Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Columbia University, New York, NY, ⁴Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Department of Medicine/Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Peptidylarginine deiminase (PAD) 2 and 4 are targets of the humoral response in RA. However, the mechanisms by which these enzymes become immunogenic in…
Abstract Number: 2794 • 2018 ACR/ARHP Annual Meeting
Peptidylarginine Deiminases Are Required for Normal Immunoglobulin G Half-Life
Mandar Bawadekar¹ and Miriam A. Shelef^1,2, ¹Department of Medicine, Division of Rheumatology, University of Wisconsin - Madison, Madison, WI, ²William S. Middleton Memorial Veterans Hospital, Madison, WI
Background/Purpose: Antibodies are a cornerstone of immunity and pathologic in autoimmunity. Immunoglobulin G (IgG) can undergo multiple different post-translation modifications, some of which can alter…
Abstract Number: 483 • 2017 ACR/ARHP Annual Meeting
Anti-Peptidylarginine Deiminase-4 Antibodies Are Present in the Sputum of RA Patients and Can Activate Peptidylarginine Deiminase-4 Enzyme Activity
M. Kristen Demoruelle¹, Hong Wang², Ryan L. Davis², A. Itzam Marin¹, Jill M. Norris³, V. Michael Holers¹, Kevin D. Deane¹ and Erika Darrah², ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²Division of Rheumatology, The Johns Hopkins University, Baltimore, MD, ³Department of Epidemiology, Colorado School of Public Health, Aurora, CO
Background/Purpose: Anti-peptidylarginine deiminase (PAD)-4 antibodies (Abs) are present in a portion of RA patients and associate with more severe joint disease, suggesting that they play…
Abstract Number: 1072 • 2017 ACR/ARHP Annual Meeting
Mutated Peptidylarginine Deiminase from Porphyromonas Gingivalis Is a Target in Rheumatoid Arthritis and Citrullinates Major RA-Autoantigens
Madeleine Jenning¹, Bianka Marklein¹, Jimmy Ytterberg², Gerd R. Burmester¹ and Karl Skriner¹, ¹Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ²Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Previous reports showed that peptidylarginine deiminase (PPAD) form Porphyromonas gingivalis (P.g.) is not able to citrullinate proteins internally. Mutated PPAD (mPPAD) from P.g. involved…
Abstract Number: 1363 • 2017 ACR/ARHP Annual Meeting
Disease Duration and Shared Epitope, but Not Smoking History, Are Associated with Peptidylarginine Deiminase 4-Antibody Development in Rheumatoid Arthritis
Laura Cappelli¹, Maximilian Konig¹, Pooja Naik², Arvin Saleh³, Allan C. Gelber³, Clifton O. Bingham III⁴ and Erika Darrah⁵, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumatology, Johns Hopkins University, Baltimore, MD, ⁵Department of Medicine/Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Clinical characteristics and biomarkers help clinicians predict disease features in rheumatoid arthritis (RA). Both peptidylarginine deiminase 4 (PAD4) antibodies and smoking have been associated…
Abstract Number: 2430 • 2017 ACR/ARHP Annual Meeting
For Each HLA-DRB1 Genotype, the Likelihood to Develop RA Correlates with the Probability of Binding at Least a Peptide from PAD4
Isabelle Auger¹, Nathalie Balandraud² and Jean Roudier³, ¹INSERM UMRs 1097, Marseille, France, ²Rheumatology, APHM, Marseilles, France, ³Arthrites auto-immunes, INSERM UMRs 1097, Marseille, France
HLA-DRB1 genotypic risk to develop ACPA positive RA correlates with capability of encoded HLA-DRB1 chains to bind Peptidyl Arginyl Deiminase (PAD4) peptides, not citrullinated Fibrinogen…
Abstract Number: 3022 • 2016 ACR/ARHP Annual Meeting
Autoantibodies to Peptidylarginine Deiminase 2 Protect Against Radiographic Progression in Patients with Rheumatoid Arthritis
Erika Darrah¹, Jon T. Giles², Ryan Davis¹, Pooja Naik¹, Maximilian Konig¹ and Felipe Andrade¹, ¹Department of Medicine, Division of Rheumatology, The Johns Hopkins University, Division of Rheumatology, Baltimore, MD, ²Columbia University, College of Physicians and Surgeons, Division of Rheumatology, New York, NY
Background/Purpose: The mechanisms that drive clinical heterogeneity and outcomes in patients with rheumatoid arthritis (RA) are poorly understood, but precise biomarkers may identify clinically unique…
Abstract Number: 3148 • 2016 ACR/ARHP Annual Meeting
Peptidylarginine Deiminase 2 Is Required for Tumor Necrosis Factor Alpha Induced Citrullination and Arthritis, but Not Neutrophil Extracellular Trap Formation
Mandar Bawadekar¹, Daeun Shim¹, Ryan Rebernick¹, Chloe Peyton¹, Chad J. Johnson², Thomas F. Warner³, Dres Damgaard⁴, Claus Henrik Nielsen⁵, Anthony P. Nicholas⁶, Ger JM Pruijn⁷, Jeniel E. Nett⁸ and Miriam A. Shelef^1,9, ¹Department of Medicine, Division of Rheumatology, University of Wisconsin-Madison, Madison, WI, ²Department of Medicine, University of Wisconsin-Madison, Madison, WI, ³Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, ⁴Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ⁵Danish Rheumatologic Biobank and DANBIO registry, Rigshospitalet, Glostrup, Gentofte and Herlev University Hospital, Copenhagen, Denmark, ⁶Neurology, University of Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL, ⁷Biomolecular Chemistry, Institute for Molecules and Materials and Radboud Institute for Molecular Life Sciences, Radboud University, Nijmegen, Netherlands, ⁸Medicine and Medical Microbiology and Immunology, University of Wisconsin-Madison, Madison, WI, ⁹William S. Middleton Memorial Veterans Hospital, Madison, WI
Background/Purpose: The presence of anti-citrullinated protein antibodies in rheumatoid arthritis points to a potential role for citrullination in disease pathogenesis. Peptidylarginine deiminases (PADs) catalyze the…
Abstract Number: 470 • 2016 ACR/ARHP Annual Meeting
Crucial Involvement of Citrullinated Proteins and ACPA in the Development of Peptide-Glucose-6-Phosphate Isomerase Induced Arthritis
Hoshimi Kawaguchi¹, Isao Matsumoto¹, Hiroshi Ebe¹, Naoto Umeda¹, Yuya Kondo¹, Hiroto Tsuboi² and Takayuki Sumida¹, ¹Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Division of Clinical Immunology, Doctoral Programs in Clinical Science, Graduated School of Comprehensive Human Science, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Various citrullinated proteins and anti-citrullinated protein antibodies (ACPA) are increased in patients with rheumatoid arthritis (RA). ACPA have high specificity for RA, and are…
Abstract Number: 570 • 2016 ACR/ARHP Annual Meeting
A Molecular Timeline for Preclinical RA Pathogenesis Defined By Dysregulated PTPN22, Hypercitrullination, and Aberrant Cytokine/Metabolic Profiles in PBMC of at-Risk Individuals
Hui-Hsin Chang¹, Nishant Dwivedi², Bo Sun², Deepak A. Rao³, Jeffrey A. Sparks³, Jennifer Kinslow⁴, Yuko Okamoto⁴, Kevin D. Deane⁵, M. Kristen Demoruelle⁶, Jill M. Norris⁷, Elizabeth Karlson², V. Michael Holers⁸ and I-Cheng Ho¹, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴University of Colorado School of Medicine, Aurora, CO, ⁵Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁶Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁷Epidemiology, Colorado School of Public Health, Aurora, CO, ⁸Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: One unique feature of RA is the presence of ACPA. PTPN22 is a phosphatase that also acts to suppress citrullination independently of its phosphatase…
Abstract Number: 1116 • 2016 ACR/ARHP Annual Meeting
Anti-Citrullinated Protein Antibodies Promote Synovial Fibroblasts Migration and Adhesion through a Peptidylarginine Deiminases (PAD) Dependent Pathway
Meng Sun¹, Vijay Joshua¹, Akilan Krishnamurthy¹, Yanying Liu², Aase Hensvold¹, Sergiu-Bogdan Catrina³, Caroline Ospelt⁴, Vivianne Malmström⁵, Khaled Amara¹, Johanna Steen¹, Muhammad Sohel Mia¹, Marianne Engström¹, Heidi Wähämaa¹, Jimmy Ytterberg¹, Bence Rethi¹ and Anca I Catrina¹, ¹Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Peking University People's Hospital, Beijing, China, ³Molecular Medicine and Surgery, Molecular Medicine and Surgery, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ⁴University Hospital Zurich, Center of Experimental Rheumatology, Switzerland, Zurich, Switzerland, ⁵Department of Medicine, Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Synovial fibroblasts (SFs) contribute to rheumatoid arthritis (RA) pathogenesis by growing into the synovial space and by producing pro-angiogenic and tissue remodelling factors, chemokines…
Abstract Number: 1119 • 2015 ACR/ARHP Annual Meeting
High Resolution Motif Mapping of in Situ Anti-Native-Vimentin Antibodies in Lupus Tubulointerstitial Nephritis
Andrew Kinloch¹, Yuta Asano², Balazs Banfai³, Gregor Dernick³, Carole Henry Dunand⁴, Nirit Mor-Vaknin⁵, Maureen Legendre⁵, David Markovitz⁵, Thomas Schindler⁶ and Marcus R. Clark⁷, ¹University of Chicago, Chicago, IL, ²Committee of immunology, University of Chicago, Chicago, IL, ³Translational Technologies and Bioinformatics, Roche, Basel, Switzerland, ⁴Rheumatology and Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ⁵University of Michigan, Ann Arbor, MI, ⁶Roche Innovation Center Basel, Roche, Basel, Switzerland, ⁷Rheumatology and Knapp Center for Lupus Research, University of Chicago, Chicago, IL
Background/Purpose: Severe lupus tubulointerstitial nephritis (TIN) is prognostic of renal failure and characterized by an in situ autoantibody response. By characterizing monoclonal antibodies engineered from…